Research and development of new antitumor drugs by Qingdao enterprises is expected to go on the market at the beginning of next year

        According to the information released by Qingdao science and Technology Bureau, the project of novaferon (English Name: novaferon), an innovative drug developed by Qingdao Jiehua Biotechnology Co., Ltd., has entered the industrial trial production The project has been listed in the major science and technology projects of "the 11th Five Year Plan" and "the 12th Five Year Plan" successively, with a supporting fund of more than 30 million yuan 。 The product is expected to go on sale at the beginning of next year, with an annual output of 30 million injections and an annual sales revenue of more than 10 billion yuan The reporter learned that Jiehua Biotechnology Co., Ltd (Jiehua Biology) is an international group company invested and managed by Chinese overseas students engaged in the research and development and industrialization of biological high-tech, aiming at the research, development and industrialization of innovative drugs for malignant tumors, major infectious diseases and immune deficiency diseases that seriously threaten human health After 16 years of research and development, JHB has established two patent technology platforms for gene modification of high active protein and long-term protein, and invented three new protein compounds with completely independent intellectual property rights: novaferon, Nova EPO, Nova GMCSF, It has successively obtained more than 100 invention patents from the United States, the European Union, China, Japan and other major countries   It is reported that lefuneng drug is a kind of recombinant high-efficiency anti-tumor and anti-virus protein injection, which belongs to the national class I new biological drug It has been identified by the National Institute for the control of pharmaceutical and biological products and compared with similar protein drugs, its anti-tumor activity is more than 200 times higher The therapeutic effect of lefuneng drug for chronic hepatitis B is far greater than that of existing hepatitis B drugs, realizing a major breakthrough in the treatment of hepatitis B The product is expected to go on sale at the beginning of next year, with an annual output of 30 million injections and an annual sales revenue of more than 10 billion yuan The official launch of the project has positive demonstration significance for improving the technical level of the field of bio medicine in the island city and promoting the scale development of the bio pharmaceutical industry, the staff said.